JEANNE OELERICH: Open Payments
NPI 1700853496 · AURORA, IL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$5,296 in 206 payments from 37 companies in 2025. Trend: 2023 $2,795 · 2024 $3,750 · 2025 $5,296
Food & beverage: $4,148Long term medical supply or device loan: $1,147
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 40 | $1,648 |
| Janssen Biotech, Inc. | 16 | $593 |
| PFIZER INC. | 17 | $355 |
| Celgene Corporation | 14 | $238 |
| Gilead Sciences, Inc. | 10 | $235 |
| AstraZeneca Pharmaceuticals LP | 9 | $216 |
| E.R. Squibb & Sons, L.L.C. | 14 | $182 |
| Eisai Inc. | 8 | $161 |
| Lilly USA, LLC | 9 | $142 |
| Incyte Corporation | 6 | $141 |
Products named: KISQALI, REBLOZYL, Trodelvy, RYBREVANT, TALVEY, Lenvima, OPDIVO, VERZENIO.
Industry payments across IL — which companies pay providers there.
